Literature DB >> 9463766

Wound healing in diabetes. Outcome and costs.

J Apelqvist1.   

Abstract

Healing of foot ulcers is limited by multiple factors that necessitate a multifactorial and multidiciplinary approach. Patients with diabetes with previous foot ulcers have a high risk for new ulcerations and further amputations and have increased mortality rates. These findings stress the need for lifelong observation of the diabetic foot. The diabetic foot is a large economic problem, and management of ulcers has not always been performed in a most cost-effective way. Cost for amputation is high to society because of prolonged hospitalization, rehabilitation, and need for home care and social service for disabled patients. A cost-effective management plan should focus not only on short-term cost until healing but also on long-term costs, because foot ulcer and especially amputation are related to increased high reulceration rate and lifelong disability. The most important action to reduce cost in management of the diabetic foot is to avoid amputations.

Entities:  

Mesh:

Year:  1998        PMID: 9463766

Source DB:  PubMed          Journal:  Clin Podiatr Med Surg        ISSN: 0891-8422            Impact factor:   1.231


  6 in total

1.  The use of marrow-derived stem cells to accelerate healing in chronic wounds.

Authors:  Lee C Rogers; Nicholas J Bevilacqua; David G Armstrong
Journal:  Int Wound J       Date:  2008-01-03       Impact factor: 3.315

2.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  The role of reconstructive microsurgery in treating lower-extremity chronic wounds.

Authors:  Hyunsuk Peter Suh; Joon Pio Hong
Journal:  Int Wound J       Date:  2019-05-30       Impact factor: 3.315

4.  The health status of diabetic patients receiving orthotic therapy.

Authors:  S Davies; O Gibby; C Phillips; P Price; W Tyrrell
Journal:  Qual Life Res       Date:  2000-03       Impact factor: 4.147

5.  Resource utilisation and costs associated with the treatment of diabetic foot ulcers. Prospective data from the Eurodiale Study.

Authors:  L Prompers; M Huijberts; N Schaper; J Apelqvist; K Bakker; M Edmonds; P Holstein; E Jude; A Jirkovska; D Mauricio; A Piaggesi; H Reike; M Spraul; K Van Acker; S Van Baal; F Van Merode; L Uccioli; V Urbancic; G Ragnarson Tennvall
Journal:  Diabetologia       Date:  2008-07-22       Impact factor: 10.122

6.  Double blind, randomized, placebo controlled clinical trial for the treatment of diabetic foot ulcers, using a nitric oxide releasing patch: PATHON.

Authors:  Sandra Y Silva; Ligia C Rueda; Gustavo A Márquez; Marcos López; Daniel J Smith; Carlos A Calderón; Juan C Castillo; Jaime Matute; Christian F Rueda-Clausen; Arturo Orduz; Federico A Silva; Piyaporn Kampeerapappun; Mahesh Bhide; Patricio López-Jaramillo
Journal:  Trials       Date:  2007-09-26       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.